Skip to main content
Tue, Apr 7, 2026
S&P 500 5,142.30 +0.87%|NASDAQ 16,284.75 +1.12%|DOW 38,972.10 -0.23%|AAPL $192.45 +1.80%|TSLA $241.80 -2.10%|AMZN $178.92 +0.54%|GOOGL $141.20 +0.32%|MSFT $415.60 -0.15%|
S&P 500 5,142.30 +0.87%|NASDAQ 16,284.75 +1.12%|DOW 38,972.10 -0.23%|AAPL $192.45 +1.80%|TSLA $241.80 -2.10%|AMZN $178.92 +0.54%|GOOGL $141.20 +0.32%|MSFT $415.60 -0.15%|
Sample data
BusinessUnited States1 sourcesNeutral

ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance

Company initiated a comprehensive review of promotional materials and is implementing enhanced advertising compliance measures, including expanded promotional review protocols, executive training, and external regulatory oversight Company has removed the identified podcast from its corporate

ImmunityBio
via ImmunityBio
ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance

Source Verification

Corroboration Score: 1

This story was independently reported by 1 sources. Click any source to read the original article.

Comments

0 comments
Be respectful and constructive.
Loading comments...